Comments Off on Mammograms, diet & exercise will not end the epidemic
Posted by IdaT on September 13, 2011
Title: Mammograms, diet & exercise will not end the epidemic
Author: Karuna Jaggar
Publication: Think Before You Pink blog / Breast Cancer Action
Publication Date: September 13, 2011
In anticipation of National Breast Cancer Awareness Month this October, Susan G. Komen for the Cure’s CEO Nancy Brinker is calling for “less talk, more action” on breast cancer. I am struck by how similar the urged “action” looks to what the organization has been advocating for years. Komen’s “take action” emphasis continues to be on individual women getting annual mammograms.
At Breast Cancer Action, we bring a markedly different understanding of what action we all need to take—for ourselves, each other, our mothers, daughters, and granddaughters—to truly end the breast cancer epidemic. Komen’s faith in mammograms to bring the “end to breast cancer” is misplaced.
Comments Off on Susan G. Komen for the Cure® – No More Apologies!
Posted by IdaT on August 12, 2011
Title: Susan G. Komen for the Cure® – No More Apologies!
Author: Nancy Stordahl
Publication: Nancy’s Point blog
Publication Date: August 12, 2011
There has been a lot of discussion recently in the blogosphere about Susan G. Komen for the Cure®. I believe the rumblings are starting to be heard. Now the question is will Komen begin to listen? Like I’ve always told my students, there is a huge difference between hearing and listening.
For the record, Komen describes itself as,
—the world’s largest and most progressive grassroots network of breast cancer survivors and activists – the only grassroots organization fighting to cure breast cancer at every stage, from the causes to the cures and the pain and anxiety of every moment in between.
In a Susan G. Komen for the Cure® blog post (Jul. 20, 2011) the organization writes;
The American College of Obstetrician and Gynecologists today recommended annual mammograms for women 40-49, modifying earlier recommendations in what Susan G. Komen for the Cure is hailing as a “victory for women’s health.”
In the same week, Nancy Brinker, Komen’s self-styled global leader of the breast cancer movement appeared on the CBS Early Show in a segment hosted by Rebecca Jarvis, and CBS’ own in-house medical attaché’, Dr. Jennifer Ashton, to discuss this latest development in mammography screening guidelines.
Ms. Brinker’s public comments and appearances are to be expected in relation to the ongoing debate about the benefits, limitations, and risks of one-size-fits-all screening guidelines. The debate has a long history, and the Komen organization has been deeply committed to mammograms for thirty years without, unfortunately, much regard for the concerns raised in the medical and scientific community that call for improved accuracy, quality, and the development of specific risk profiles to determine which groups of people have the greatest chance of benefitting from screening.
However, Brinkers’ appearances at this point in contemporary history involve more than the simple offering of an “advocate perspective” on screening. Brinker consistently uses her message to sell her brand.
Nancy Brinker on CBS Early Show
Although a departure from her usual pink ensemble, Ms. Brinker appeared resplendent on the CBS Early Show wearing a tailored orange jacket embroidered with Komen’s trademarked running ribbon logo. As the key figure head for Komen’s pink-ribbon brand, most of Ms. Brinker’s outfits feature the trademarked running ribbon. The Komen organization imprints the logo on a multitude of products from t-shirts to eggs to perfume to their founder. To our knowledge Brinker has yet to have the running ribbon tattooed on her body.
Dr. Jennifer Ashton on CBS Early Show
As reporters, pundits, individuals, and MDs set up camp on one side or the other of the mammogram screening war zone they too get caught up in the branding.
CBS’s own medical reporter, Dr. Jennifer Ashton, had Komen’s embroidered logo on her blouse. Is Dr. Ashton an employee of the Komen organization? Is CBS running an advertorial for Komen? Is the television spot another marketing strategy involving Komen product placement? Thankfully the host, Rebecca Jarvis, appeared to be trademark-free perhaps to indicate that CBS was committed in some regard to a more objective discussion of the issue.
Screenshot of CBC Early Show segment
In the CBS video, Dr. Ashton outlined three of the more recent mammogram screening recommendations about when an average risk woman should begin screening and with what frequency. This is not an exhaustive list of organizations offering recommendations on screening, but it includes the American College of Obstetricians and Gynecologists (ACOG), the American Cancer Society (ACS), the National Cancer Institute (NCI) and the U.S. Preventive Services Task Force (USPSTF).
The simple difference in these guidelines begs an important question that Ms. Jarvis asked of Ms. Brinker;
“Why can’t they get together and pool their data and come to one conclusion on this?”
Fascinating question, Ms. Jarvis! As the “leader” of the global breast cancer movement Komen would be in a strong position to convene and moderate such a meeting of the minds. Review the data. Establish strong and objective standards for analyzing the data. Identify gaps. Point out risks, benefits, and limitations. Determine the conditions under which screening works for particular groups of women. The USPSTF actually did this already. Here’s a video with one of the members of the task force, Dr. Russ Harris, discussing the information. But okay, let’s bring more groups to the table. Why not? Clearly, there is A LOT at stake in this issue. Instead of engaging the question, Ms. Brinker said this;
“Well, we’ve had a conclusion for many, many years at Susan. G. Komen, almost a generation. Screening saves lives. The 5-year survival rates for breast cancer diagnosed early is 98 percent…and this is largely due to screening and early diagnosis.”
Ms. Brinker believes, and therefore Komen believes, that screening saves lives. Specifically, mammography screening. Not MRI. Not ultrasound. Not access to quality care. Not newer and better treatments. Not targeted therapies. Not biological, genetic, and molecular factors that are yet unknown. Not avoiding the disease in the first place. Screening. Brinker’s unflinching attachment to this 30-year-old conclusion is astounding. By stating this message over and over in an echo chamber, she loses sight of the forest for the trees. Even ACOG – which supports the general age 40 annual screening guideline – admits openly:
“What’s clear is that guidelines aren’t hard and fast rules,” says Thomas J. Herzog, MD, clinical professor of obstetrics and gynecology at Columbia University Medical Center in new York City. “Guidelines often need to be individualized to the patient.”
Guidelines, Ms. Brinker, aren’t hard and fast rules. Your new best friend ACOG said so. Yet Brinker lives in a world that relies on hard and fast rules. Screening saves lives. Buy the brand. End of story. In an attempt to delegitimize the Task Force that reached a conclusion different from hers, Brinker remarked;
“…The Healthcare Prevention Taskforce was highly confusing twenty months ago when they took this on, because they were scientists looking at data that most of us already knew.”
This statement deserves some active listening. The Healthcare Prevention Taskforce to which Brinker refers is the U.S. Preventive Services Task Force (USPSTF) – a government mandated working group, that is
“…[a]n independent panel of non-Federal experts in prevention and evidence-based medicine and is composed of primary care providers (such as internists, pediatricians, family physicians, gynecologists/obstetricians, nurses, and health behavior specialists).”
The USPSTF did not “take this on.” They were mandated to systematically and comprehensively investigate and analyze the existing data on screening. Of all of the groups who have made recommendations on the subject it is, in reality, the only body that does not have a clearly vested stake in the findings. This is not to say that the merit of the findings, the procedures used, and the translational capacity of the conclusions should not be evaluated in their own right. They should. But there is no conflict of interest concerning this group of investigators and the issue at hand. And, if “most of us” already “knew” about that data, then why didn’t this information come out ten years earlier? Wait, it did. In 2001 a critical review of the clinical trials on screening was published in the medical journal The Lancet. It pooled the results and found only a 16% reduction in the risk of dying of breast cancer for women who were screened.
Komen, on the other hand, does have a vested interest in screening. It has been the organization’s rallying call for three decades. It comprises the bulk of Komen’s messaging and has become the raison d’etre of its existence (besides selling pink-ribbon products). Komen spends some money on research (as we have pointed out previously), but the bulk of the program spending is in “education.” What are people educated about? Screening. And the education stops with “Get your mammogram. It saves lives.”
Ms. Brinker brings the point home in her rhetorical monologue when she shares her vision of the future;
“Mammography is not 100% perfect. It should be. We have the ability to make it perfect in the U.S. today. It’s political will. You know it should be more accurate.”
It would be nice if mammograms were 100% perfect. Agreed. If they didn’t have a rate of false positives that approached 80%. If they didn’t miss 25-40% of tumors that were cancerous. If they could indicate whether a pre-cancer would progress or not into something dangerous. If “perfection” were achieved, however, the result would be a reduction in overtreatment and overdiagnosis (a good thing), but based on current knowledge about breast cancer and treatment it is not likely to reduce the number of deaths from the disease, and it would do nothing in terms of prevention. It would do a better job of diagnosing cancers, perhaps, but it would not stop people from dying of breast cancer.
Ms. Jarvis then asks Ms. Brinker to clarify what she means by “political will.” Given that the federal government enacted the Breast and Cervical Cancer Mortality Prevention Act (1990) to insure access to screening for low-income, uninsured, and underinsured women and the Breast and Cervical Cancer Treatment Act (2000), which gives States the option of providing Medicaid coverage to low-income, uninsured and underinsured women, under 65 years of age, who have been screened and diagnosed through the National Breast and Cervical Cancer Early Detection Program and need treatment, political will does not seem to be at issue with regard to a commitment to screening. Acknowledging the limitations of screening, the lobbying of technology manufacturers, and the development of new diagnostic tools is another story.
Unfortunately Ms. Brinker does not attend to these issues or give any clear account of her perception of political will. She discusses the ability of airport screening technology to see what people have eaten. How this relates to the diagnosis of malignant breast cancers eludes us. Instead Ms. Brinker reins in the discussion to Komen’s agenda on screening mammography;
“[B]ut the issue is it does work. It works. It works in a broad population and people are now living longer because of it.”
It does work. Sometimes. Depending upon the study cited there has been a documented reduction in mortality due to screening that is somewhere between 10 and 30 percent. That’s a pretty low percentage really. But Nancy just repeats over and over. It works. It works. It’s a “victory for women’s health.“
What about the 5 to 50% of people who are overdiagnosed?
What about the 20 to 30% of people who are over-treated, sometimes for conditions that are not life-threatening?
What about the estimated one-third of the people considered to be “cured” of breast cancer who will then have a recurrence or develop metastatic disease, even those who were diagnosed at an early stage?
What about the fact that the actual number of women and men dying from metastatic breast cancer has hovered around 40,000 per year, with no significant decrease since 1990?
Do any of these statistics feel like a “victory for women’s health?”
As the largest breast cancer fundraising and advocacy organization in the world, we expect more from Komen. Why is the Komen organization not asking these questions? Why are they aggressively promoting a stance on screening that is clearly questionable given existing evidence? Why is Komen avoiding the complicated questions and concerns that others have about screening? Isn’t it Komen’s job to advocate for the best interests of the entire breast cancer community? Doesn’t that include pragmatic criticism and scientific analysis of existing research as well funding new research to answer lingering questions?
A victory for women’s health would be eradication of breast cancer. Not a screening technology, which is diagnostic at best, and doesn’t reduce the chances of dying from breast cancer for 70 to 90 percent of the population.
Where’s the advocacy, Komen? Who do you work for?
KomenWatch grants full permission to republish our editorials in their entirety, with proper citation and link.
This past Sunday was of course Mother’s Day. It was also the day earmarked for the Susan G. Komen Race for the Cure at the Mall of America in Bloomington, MN. (I live close to the Twin Cities and lived there for many years, hence my interest). While watching the news Sunday night and observing the anchors beaming and smiling, I found myself feeling fidgety, uncomfortable and yes, even guilty because I was not feeling what I was supposed to be feeling. I was not feeling all warm, fuzzy and grateful. In fact, I was feeling the opposite. I was feeling a bit ungrateful. Why?
The story was meant to be of the warm and fuzzy type, the kind of story that makes everyone watching feel good, it was Sunday evening after all. And not just any Sunday evening, Mother’s Day Sunday evening.
The news clips captured yet another sea of pink, another shining example of the success of the pink ribbon campaigns.
The event drew in 55,000 walkers, a new record, and 2.5 million dollars were raised. The anchors proudly stated this particular race has grown to be the second largest in the world, probably due to the Mother’s Day date as well as the location; again, it takes place at the Mall of America.
Leaders magazine, a “worldwide magazine that deals with the broad range of leadership thoughts and visions of the world’s most influential people,” recently interviewed Nancy Brinker, Founder and Chief Executive Officer of Susan G. Komen for the Cure. In the article titled “A Large Mission” Brinker discussed Komen’s work, progress, and intentions for the future.
The article began in the usual way, reminding readers of Nancy’s famous promise to her dying sister Suzy, a promise to do whatever she could to end breast cancer. Then she stressed, as she often does, that Suzy had faced breast cancer at a time when the social climate surrounding breast cancer was one of “invisible silence.” It’s true that the C word was only ever murmured with hushed tones if at all, and breast cancer was then a silent killer. Brinker stressed that she wanted to “end the shame and hopelessness” caused by breast cancer. In articulating her desire to do something to fulfill her promise to her sister, she stated further;
We saw the weaknesses in the system. People didn’t know how little money was going to research at the time – only $20 to $30 million of support for breast cancer research was coming to the National Cancer Institute, which was fairly new at the time.
With this statement readers learn (or remember) that prior to the rapid expansion of breast cancer advocacy in the late 1980s and early 1990s there had been a dearth of breast cancer research. Nixon’s war on cancer had only been declared in 1971 and the National Cancer Institute was still an immature entity at the time of Komen’s founding in 1982.
Brinker’s statement about research might even lead readers to assume that research was a major impetus behind its stated mission, to “cure” breast cancer. After all, how might a disease be cured? Treatment, and the research used to find, evaluate, and improve treatment. Accurate diagnostics, and the research used to develop, test, and refine diagnostics. Prevention, and the research used to locate the causes of a disease, learn its pathways, and prevent it from occurring in the first place. Education, based on the evidence amassed from bodiesofsystematicresearch. Cure relies on research. There’s no reasonable way around it.
Unfortunately, something odd happened on the way to the cure. After thirty years in the nonprofit foundation business, research is no longer the focal point if it ever really was. In fact, today Brinker frequently argues that research is a “helpful” component but not the pathway to eradication. Nancy states;
It’s always helpful to support research, but it’s not enough to do that; if you want to eradicate death by disease, you have to involve every sector of society…To that end, we have more than 120 affiliates throughout America, all of whom are grassroots based organizations who leave 75 percent of what they raise in their communities, focused on low resource people. So they provide education, screening, and some treatment, while 25 percent of what they raise goes back into our national grant pool.
Education. Screening. Some treatment. And a national grant pool. We’re baffled. In 1982 research seemed to be a key mechanism to finding a cure. The National Breast Cancer Coalition continues to prioritize research funding through the Department of Defense and has set a new deadline to reorient research efforts in a coordinated way. Community-based organizations around the nation have formed their own partnerships with researchers and clinics because there isn’t enough research being done on a federal level. Yet 25 percent of monies raised by affiliates are sent back to Komen central allegedly for research.
Okay, how does it add up?
As one of our archived articles reports succinctly from Komen’s own audited financial statements, Komen’s research program in 2010 comprised only19% of the organization’s total resources. The remainder went to education (37%), screening (12%), some treatment (5%), fundraising and other general overhead (27%). Research clearly is not the priority for the organization, and Brinker brings this point home in the Leaders interview stating, “it isn’t useful to just fund research.” The pie chart below is a visual representation of where Komen’s commitments lie.
Program Services & Other Expenses 2010
Source: The Cancer Culture Chronicles blog
Okay, we get it Nancy. It isn’t useful to just fund research. That’s why it’s such a small part of Komen’s program budget. Brinker reiterates this point;
Today, knowing what we know, it isn’t useful to just fund research; to say you’re helping one woman at a time is not enough. You need to fund the research, but also to make sure that as you’re doing that, the clinical changes are occurring.
Is ensuring clinical change part of Komen’s program allocations? Where is that? How is it accomplished?
At the same time that Nancy Brinker and Komen clearly perceive research to be a minor part of curing breast cancer, the leadership fights over ownership of the trademarked phrase “for the cure” [i.e., see the articles under the category lawsuits] and consistently talks about its strong commitment to research over the years despite the fact that they believe it to be a minor part of eradicating the disease.
Just this week Komen issued another effusive press release in which Komen announced that it will fund $55M toward research grants at 56 institutions across the United States and internationally, with $3M granted to support various patient support conferences and programs in 2011.
Susan G. Komen for the Cure® Commits Nearly $58 Million in 2011 to Tackle Toughest Issues with New, Innovative Approaches to Breast Cancer Research
Global Breast Cancer Leader Focuses on Development of Breast Cancer Vaccine, Creating More Effective Therapies and Reducing Disparities in Treatments for African Americans and Other Ethnic Groups
That’s interesting. It sounds like a lot of money too. Note that $58M is a decrease of about $17M from last year’s research allocation. Why the decline in research funding? Komen had record revenues in 2010 of $389M. Maybe research is getting less and less important to finding a cure for breast cancer. At a whopping $58M, only15percent of Komen’s resources for 2010 were allocated to research the following year.
Yet, the number ringing in our ears from Brinker’s regular statements about the “national grant pool” is that 25percent of money raised from affiliates goes to research. Unfortunately, that’s 25 percent of a different number altogether. The Komen shell game plays on as Brinker herself touts the organization’s funding of cutting-edge research. She states,
Our goal at Komen is to fund research with the greatest potential to make a difference and save lives in the shortest period of time. That means putting our dollars toward cutting-edge research that is high-risk, with potentially huge rewards.
Okay, we’re baffled again. If research is not Komen’s priority when it comes to funding, how can the organization expect to “make a difference and save lives in the shortest period of time.” High risk research could potentially result in some great finding that moves the state of science forward in such a profound way that cure is just around the corner. Maybe. But that’s not how medical research has worked in the past. Science moves in fits and starts. Incremental at best. Breakthroughs happen, sure. Wouldn’t Komen increase the odds of breakthroughs in science if it funded more research?
And what does Brinker mean by the “shortest period of time?” How exactly is that to be measured? Someone diagnosed with stage 4 breast cancer is likely to want to see the shortest period of time as sometime about…NOW. That’s unlikely, we admit. Will it happen next year? In ten years? Should we wait another thirty years and keep throwing pink parties in the meantime to celebrate minor successes? When asked by Leaders whether she felt we were any closer to finding a cure, Nancy Brinker said,
I believe we’re about halfway there. For 20 years, most of our research funding went to cancer biology. Now we’re focusing only on taking that biology and moving it toward a translational component.
Okay, 20 years. Is that the “shortest period of time?” What does it mean to be halfway to a cure anyway?
Time is important to a cancer patient. Ten years or twenty years makes a huge difference. It’s important to researchers and physicians too who want to do the best for their patients. Treat them well. Give them hope for a future. It’s not nice to throw around time frames without a clear plan to back it up. And what does Nancy mean when she goes on to say that,
The board asked me to take over as CEO to shape and fashion the organization because we’re all working on the 2020 plan…..
What is the 2020 plan? That’s ten years from now. Clock ticking. Is she referring to the the National Breast Cancer Coalition’s 2020 Deadline, the campaign oriented to eradicating breast cancer by 2020? Or does Komen have it’s own 2020 plan?
We really hope Nancy will tell us WHEN we can expect to “end breast cancer forever,” and how Komen will achieve this lofty goal without making research the priority.
KomenWatch grants full permission to republish our editorials in their entirety, with proper citation and link.
Starring: Nancy Brinker, CEO and Founder of Susan G. Komen for the Cure®
Date: June 23, 2010
Youtube videos have become the TV commercials of the digital age. This 32-second video clip of Nancy Brinker advertising the “behind-the-scenes” work of the Komen foundation is essentially the same thing. This particular clip represents something new for Komen in that it does not mention a promise to a dying sister and instead acknowledges the public visibility of Komen “t-shirts” and the relative invisibility of the inner workings of the organization. Brinker states that, people don’t see Komen’s hundreds of research grants, thousands of free screenings for low-income women, and millions of volunteers working [on something unspecified] late into the night all with the hope of someday making breast cancer itself invisible.
Interesting commentary given the numerous critiques and concerns raised in recent years about: Komen’s relatively small percentage research allocations; superficial approach to breast cancer education and awareness; and obsession with branding, corporate partnerships, and trademark issues. Could these concerns be the spark for Brinker’s half-minute response?
After decades of being seemingly untouchable, Komen is on the defensive. The organization has refocused its public relations exercises, cleaned its website, and made public statements like this one from Brinker. Unfortunately, there have been no in-depth responses to the valid concerns that continue to be raised about the organization’s:
misrepresentation of the realities of the disease
skewed program allocations
ongoing misinformation about the role of mammograms and “awareness” as keys to the eradication of the disease
lack of ethical review processes concerning corporate contributions and “pinkwashing”
failure to cooperate with other breast cancer organizations
If Komen’s strategies have not reduced breast cancer incidence, rates of recurrence, or the number of deaths from metastatic disease, how will these same strategies work to “end breast cancer forever?” They won’t. They will only bring in money, pretty up the disease, create entertaining past-times for consumers, alienate the diagnosed who don’t fit Komen’s pretty pink model, divert resources from other organizations and research priorities, and yes, fortify the t-shirt industry. They won’t end the disease no matter how many commercials Nancy Brinker makes.
There’s still so much we still don’t see.
KomenWatch grants full permission to republish our editorials in their entirety, with proper citation and link.
Title: Komen By The Numbers: 2010 and Still No Answers
Author: Anna Rachnel
Publication: The Cancer Culture Chronicles
Publication Date: March 16, 2011
Stewardship: the conducting, supervising, or managing of something; especially : the careful and responsible management of something entrusted to one’s care.
In September 2010, Susan G. Komen for the Cure® (“Komen”), proudly announced they had received a four-star rating from Charity Navigator, a popular charity evaluator whose reports are accessible by the general public.
“Achieving Charity Navigator’s highest rating for fiscal soundness is an incredible achievement for even one year during these economic times,” said Ambassador Nancy G. Brinker, Komen’s founder and CEO. “But to garner this rating four consecutive years is a true testament to the hard work of our entire Susan G. Komen for the Cure family. My gratitude also goes out to our Affiliates, our volunteers and our staff, who have proven once again to be responsible stewards of our contributors’ money as everyone continues to try to fulfill our promise of saving lives and ending breast cancer forever.”
Essentially, Charity Navigator evaluates charities based on their “organization efficiency” and their “organizational capacity”, which speaks to how sustainable an organization is. Charity Navigator then uses the results of this evaluation to assign rating stars; zero stars being the lowest to four stars being the highest. A four-star or “exceptional” rating means that a charity “exceeds industry standards and outperforms most charities in its Cause”. In the words of Charity Navigator;
“By utilizing our ratings, givers can truly know how a charity’s financial health compares with other charities throughout the country. Givers can be confident that in supporting those charities rated highly by Charity Navigator, they will be supporting organizations that are fiscally responsible and financially healthy.”
This all sounds very nice, but what does all this really mean?
“[Y]et public education is a popular mission for many of our breast cancer charities. If the goal is to educate, it’s a relatively easy mission to fulfill. Produce educational resources – mission accomplished. But it’s an expensive undertaking, even though it’s not necessarily helping to reduce breast cancer incidence.
A Closer Look At Komen’s Education Program
Continuing my series of investigations into the activities of our nation’s largest breast cancer fundraiser, Susan G. Komen for the Cure® (“Komen”), in this post I shine the spotlight on Komen’s Education program. (Previous posts in this series are available at “Komen By The Numbers” and “Komen By The Numbers: The Context of Research”.)”
Title: Komen By The Numbers: The Context of Research
Author: Anna Rachnel
Publication: The Cancer Culture Chronicles
Publication Date: January 30, 2011
“Context: the parts of a discourse that surround a word or passage and can throw light on its meaning.
Context is an important word, particularly within the cancer culture. We hear those three little words; “You have cancer”, and immediately we are thrown into a frightening void, where often the first battle is understanding the world into which we have just been forced. After shedding our tears, and numbing ourselves to the shock and pain of it all, we take a deep breath and start asking the questions we are supposed to ask. After we have figured out which questions we need to ask. Soon we begin to understand this new context. Our diagnosis, options for treatment, and how our lives will be irreparably changed. Context provides some comfort in the form of clarity, but we can’t get there unless we ask the relevant questions.
It is with this in mind, that I continue my investigation into the activities of our nation’s largest breast cancer fundraiser, Susan G. Komen for the Cure® (“Komen”). I still have questions.”
“Living with metastatic breast cancer is a bit like playing an evil game of Whack-A-Mole. Chemotherapy, at this point, is more art than science. Tumors come up and tumors go down and you never quite know where they’re going to strike next. You just keep whacking those pesky tumors and if new ones come up, you whack ’em again, and again, and again. You just hope that you have enough chemotherapy hammers in your arsenal to be able to keep whackin’ ’em before you lose the game.
In recent months, I’ve been following with interest the debate in the blogosphere, over the Susan G. Komen for the Cure® (“Komen”) lawsuits with respect to apparent trademark violations over other charities using the phrase “for the Cure”. Komen argues that trademarking the phrase, and protecting that trademark through legal strategies, is a form of stewardship of donor funds. Many others see it differently. Indeed, the debate itself is also starting to feel like a game of Whack-A-Mole because as one question comes up, it’s debated by some and whacked by others as Komen offers a superficial response. In turn, the organization’s official statements cause more questions to come up. Whack! And so the game goes on.”
Nancy Brinker / Tavis Smiley Interview
Tavis Smiley interviews Nancy Brinker, CEO and founder of Susan G. Komen for the Cure. Original air date: October 1, 2010
The Colbert Report
Comedien, Stephen Colbert takes aim at Komen’s trademark lawsuits against smaller charities. Original air date January 3, 2011
KomenWatch Grants Full Permission to Republish KW Editorials in their Entirety, with Proper Citations and Links. Editorials Include Information on How to Cite!
Quotable Quotes
"The scent of compassion and courage. The first official fragrance to benefit Susan G. Komen for the Cure®, Promise Me offers a unique opportunity to contribute to breast cancer research and recognize those who have been touched by the disease...
Read More
The Komen organization imprints the logo on a multitude of products from t-shirts to eggs to perfume to their founder. To our knowledge Brinker has yet to have the running ribbon tattooed on her body.
KomenWatch 